Patent intelligence · US
US 7202262
Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
Patent details — US 7202262
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 10, 2007
- Expiration
- Apr 5, 2027
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/4245, A61K31/4439, A61K31/454
Quick answer
US 7202262 (Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Apr 10, 2007. Expires Apr 5, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/4245, A61K31/4439, A61K31/454, A61K31/4545, A61K31/5377
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 7202262?
US 7202262 (Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Apr 10, 2007. Expires Apr 5, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7202262?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 7202262 expire?
Our index shows an expiration date of Apr 5, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.